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Background: Type 2 diabetes mellitus has well known deleterious effects on coronary artery disease (CAD). The
role of milder hyperglycemic states such as prediabetes (PD) on CAD is debatable. Glycated hemoglobin (HbA1c)
has recently been advocated as a diagnostic tool for diabetes mellitus (DM) and PD. This study aims to assess the
cardiometabolic risk profile and coronary lesions of patients with PD undergoing coronary angiography identified
either by fasting plasma glucose (FPG) or HbA1c levels.
Methods: We studied 514 individuals without previously known glucose disturbances. Their glycemic status was
assessed by FPG and HbA1c (HPLC) and classified according to ADA guidelines, using each parameter
independently, as having normal glucose tolerance (N), PD, or DM. CAD was defined as stenosis greater than 50%
in one major coronary vessel or branch. Framingham score was calculated.
Results: Subjects with PD had a similar frequency of CAD compared do N individuals by both FPG (61 vs. 59.3%)
and HbA1c (55.4 vs 61.2%) (p non-significant for linear-by-linear association). PD individuals identified by FPG had worse
HOMA2B (mean [95% CI] 65.4 [60.9-69.9] vs. 76.6 [71.4-81.9]) and HOMA2-IR (1.10 [0.98-1.22] vs. 0.80 [0.72-0.89]) when
compared to N controls. PD individuals identified by HbA1c had higher frequency of Framingham risk above 20% (25.4
vs 11.8%), arterial hypertension (87.8 vs 72.6%), and dyslipidemia (83.8 vs 72%) compared to N individuals. PD associated
with an increased number of coronary lesions only when diagnosed by HbA1c (median [interquartile interval] 2 [0–4]
PD versus 1 [0-3.75] N, p = 0.03 for trend).
Conclusions: HbA1c was more effective than FPG in identifying individuals with PD associated with high
cardiovascular risk profile in a sample of individuals undergoing coronary angiography.
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It is well established that patients with type 2 diabetes
mellitus have a higher risk of developing atherosclerosis
and cardiovascular disease (CVD) than non-diabetic in-
dividuals. This condition accounts for the majority of
deaths in individuals with diabetes mellitus (DM) [1].* Correspondence: fernando.giuffrida@me.com
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unless otherwise stated.Acceleration of atherosclerosis in the diabetic milieu is
supposed to be related to different mechanisms such as
insulin deficiency, insulin resistance, and other meta-
bolic alterations usually associated with type 2 diabetes
like arterial hypertension and dyslipidemia [2,3]. These
classical risk factors, including glycemic control itself,
are associated with both presence and severity of coron-
ary artery disease (CAD) in type 2 diabetes [4].
Undiagnosed hyperglycemia is a common finding in
acute coronary syndromes and active search for this dis-
order in the inpatient population is warranted [5]. Also,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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patients submitted to elective coronary angiography have
alterations in glucose levels such as type 2 diabetes and
prediabetes (PD), most of them being unaware of their gly-
cemic status. The role of milder hyperglycemic states such
as PD on CAD remains largely unknown. Some studies
suggest that individuals with PD have an unfavorable
metabolic profile with more cardiovascular risk markers,
being at increased risk of type 2 diabetes and CAD [6,7].
Moreover, there is still a strong debate whether individ-
uals with PD identified by different parameters would
present different metabolic patterns and related cardiovas-
cular risk. In this regard, we have several tests to identify
PD such as fasting plasma glucose (FPG), oral glucose tol-
erance test (OGTT), and more recently the use of
hemoglobin A1c (HbA1c) levels [8]. HbA1c has a poor
correlation with FPG, but there is an ongoing debate in lit-
erature about which one identifies individuals at a higher
cardiometabolic risk and at the same time suffers less
diagnostic interference from CAD itself [7-9]. The import-
ance of this discussion lies on the possibility of identifying
individuals at increased risk of CVD in order to offer more
specific preventive measures.
In this study we aim to assess whether the frequency
of CAD, its severity, and cardiovascular risk markers are
different in patients with PD diagnosed by FPG and
HbA1c classification criteria as compared to type 2 dia-
betes and normoglycemic subjects.
Methods
A total of 813 consecutive patients who underwent cor-
onary angiography at Hospital São Paulo (at the Federal
University of São Paulo) were enrolled in the present
study. Individuals with previously diagnosed DM were
excluded, resulting in 514 eligible patients. Study sub-
jects, individually and/or as a group, had mixed ethnic
background (African, Amerindian, Asian, and European
Caucasian of several different countries of origin), reflect-
ing the heterogeneity of the Brazilian population [10].
A blood sample was drawn before coronary angiography,
after an overnight fast for analysis of FPG, plasma insulin,
HbA1c (HPLC, reference value: 4.5-6.0%), lipid profile
(total serum cholesterol, LDL-cholesterol, HDL-cholesterol,
and serum triglycerides), TSH, and creatinine levels. Glom-
erular filtration rate was estimated using the Modification
of Diet in Renal Disease (MDRD) study equation [11]. Insu-
lin resistance and beta-cell secretion were estimated by
HOMA2-IR and HOMA2B indexes respectively, calculated
by previously described methods [12].
Patients were referred to coronary angiography by their
physicians for various reasons, including presence of
stable angina, a positive stress test, or for preoperative
evaluation for cardiac valvular disease or peripheral vascu-
lar disease surgeries. Clinical data as well as personal andfamily history of cardiovascular disease, DM, and associated
diseases were obtained by interview and medical examin-
ation by one member of the research group. Patients had
their glycemic statuses assessed by FPG and HbA1c levels.
They were classified by both criteria according to ADA
guidelines in normal (N), PD, and DM [8]. For the purpose
of this investigation, CAD was defined as any stenosis >50%
in at least one major coronary vessel or branch. We further
computed the number of significant coronary lesion (sten-
osis greater than 50% on angiography), as a parameter to
verify the extent and severity of visible CAD [4].
Arterial hypertension was defined as systolic blood
pressure (SBP) ≥ 140mmHg and/or diastolic blood pres-
sure (DBP) ≥ 90mmHg, or SBP and DBP below these
values in the presence of antihypertensive medication and
history of arterial hypertension. Subjects were considered
to have dyslipidemia either if levels of LDL-cholesterol
were ≥160mg/dL, HDL-cholesterol below 40mg/dL in
men and 50mg/dL in women, triglycerides >200mg/dL, or
in the presence of use of lipid lowering medications (sta-
tin/fibrates) [13].
The Framingham score was calculated as described else-
where [14]. In brief, gender, age, LDL-cholesterol levels,
HDL-cholesterol levels, SBP, DBP, presence of DM, and
current smoking status were used to calculate the 10-year
risk of CAD. Individuals with calculated risk above 20%
were considered as high risk for coronary events [15]. All
participants gave written informed consent. The study was
approved by the ethics committee of UNIFESP.
Besides previous DM, exclusion criteria included a cre-
atinine clearance lower than 50 mL/min, abnormal thyroid
function, the presence of active inflammatory disease or
neoplasia, or anemia (Hemoglobin < 10 g/dL), conditions
that could potentially interfere in some of of the laboratory
measurements performed or in the presence of CAD itself.
Patients with acute coronary syndromes and ST segment
elevation have been excluded because thrombotic events
could overestimate stenosis.
Comparisons of continuous variables among normal,
PD, and DM groups were made by ANOVA. Means and
95% confidence intervals (CI) were recorded, instead of
means + SD, to enable comparisons between individuals
classified by both FPG and HbA1c, since these don’t rep-
resent different subgroups, but the same individuals
grouped differently. Number of coronary lesions was
assessed by Jonckheere-Terpstra test, p values for trend
were recorded. Categorical variables were assessed by
Mantel-Haenszel test and p for linear-by-linear association
was recorded. A two-tailed value of p < 0.05 was consid-
ered statistically significant.
Results
When classified by the FPG criterion, individuals with
PD had similar demographic and clinical characteristics
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sure, and lipid levels compared to other groups. They
had higher FPG and HbA1c levels (by definition), as well
as higher insulin resistance and lower beta-cell function
assessed by HOMA indexes, when compared to N
individuals. DM individuals had only higher FPG and
HbA1c levels, being also more insulin resistant when
compared to both N and PD individuals. Beta-cell
secretion of these individuals was similar to the other
groups (Table 1). No differences among the three
groups divided according to the FPG criterion were
observed regarding the presence or total number of
coronary lesions and frequencies of individuals having
Framingham Risk Score above 20%, arterial hypertension,
and dyslipidemia (Table 2).
When classified by the HbA1c criterion, individuals
with PD had also similar demographic and clinical char-
acteristics such as age, BMI, abdominal circumference,
blood pressure, and lipid levels when compared to the
other two groups. They had higher glycemic parameter
levels (also by definition), but HOMA indexes were not
different between PD and N. DM individuals had higher
FPG and HbA1c levels, and were more insulin resistant
than both N and PD (Table 3). Regarding cardiovascular
risk markers, total number of coronary lesions, Fra-
mingham Risk Score above 20%, arterial hypertension,
and dyslipidemia showed a linear and positive associ-
ation with N, PD, and DM categories divided by HbA1c
(Table 4). Frequencies of individuals utilizing anti-
hypertensive or lipid-lowering medication were similarTable 1 Clinical and laboratory features of individuals classifi
Classific
Normal (FPG < 100 mg/dL) P
n (%) 271
Age (years) 59.0 (57.7-60.4)
Weight (kg) 72.0 (70.2-73.8)
BMI (kg/m2) 25.9 (25.2-26.6)
Abdominal circumference (cm) 96.0 (94.1-97.6)
SBP (mmHg) 134.4 (131.8-137.0)
DBP (mmHg) 78.3 (76.5-80.0)
FPG (mg/dL) 91.2 (90.5-91.9)
HOMA2B 76.6 (71.4-81.9)
HOMA2-IR 0.80 (0.72-0.89)
HbA1c (%) 5.76 (5.70-5.81)
HbA1c (mmol/mol) 39.3 (38.7-39.9)
LDL (mg/dL) 100.5 (96.1-104.9)
HDL (mg/dL) 41.0 (39.5-42.7)
Triglycerides (mg/dL) 136.4 (126.4-146.3)
Values expressed in means (95% CI). *p < 0.05 vs. Normal; **p < 0.05 vs. Normal ANDbetween groups, regardless of using FPG or HbA1c as
the grouping criterion.
Discussion
Our study suggests that the use of HbA1c for the diag-
nosis of PD identifies individuals with more cardiovascu-
lar risk factors than the use of FPG in a high-risk
population of individuals undergoing coronary angiog-
raphy, as assessed by the Framingham score. PD individ-
uals diagnosed by HbA1c also presented more severe
CAD when compared to N subjects. This profile was not
seen in PD individuals identified by FPG.
As expected, glycemic variables and HOMA indexes
were different in individuals divided by FPG, since this
measurement itself is used in the HOMA calculations.
Interestingly, even though they demonstrated worse
HOMA2B and HOMA2-IR as compared to normogly-
cemic subjects, individuals with PD did not show other
differences in cardiometabolic risk profile. In the identi-
fication of hyperglycemia, the use of FPG, 2-h postload
glucose, and HbA1c are associate with distinct patterns
of insulin sensitivity and insulin secretion, which could
possibly explain these findings [16]. For example, PD
identified by FPG is related to both hepatic insulin re-
sistance and reduction in first-phase insulin secretion,
leading to excessive fasting hepatic glucose production. In-
dividuals with impaired glucose tolerance (IGT) have
muscle insulin resistance along with defective late insulin
secretion [17]. HOMA2B and HOMA2-IR were not differ-
ent between PD and normoglycemic subjects identified byed according to FPG levels
ation according to fasting plasma glucose
rediabetes (FPG 100–125 mg/dL) Diabetes (FPG ≥ 126 mg/dL)
210 31
59.5 (58.2-60.9) 59.0 (56.2-60.2)
72.87(70.8-74.6) 77.2 (71.0-83.4)
26.4 (25.6-27.1) 28.8 (26.6-27.1)
97.4 (95.7-99.1) 98.9 (93.3-104.6)
140.0 (136.6-143.4) 138.3 (130.7-145.9)
82.4 (80.2-84.6) 81.7 (76.3-87.0)
108.6 (107.8-109.5)* 141.3 (135.3-147.4)**
65.4 (60.9-69.9)* 68.7 (53.4-84.0)
1.10 (0.98-1.22)* 2.49 (1.69-3.29)**
5.93 (5.86-5.99)* 6.65 (6.30-6.99)**
41.2 (40.4-41.8)* 49.1 (45.3-52.8)**
108.9 (103.8-114.0) 101.8 (87.8-115.9)
41.0 (39.4-42.5) 42.0 (36.2-47.8)
140.9 (131.0-150.7) 155.9 (123.0-188.8)
Prediabetes.
Table 2 Coronary lesions and cardiovascular risk factors
of individuals classified according to FPG levels
Classification according to FPG
Normal Prediabetes Diabetes p
n 271 210 31
Total coronary lesions 2 [0–4] 2 [0–4] 2 [0–4.25] NS
Framingham risk ≥ 20% (%) 15.1 25.4 6.9 NS
CAD (stenosis > 50%) (%) 59.3 61.0 65.6 NS
Hypertension (%) 80.5 86.2 87.5 NS
Dyslipidemia (%) 80.7 82.1 71.9 NS
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combining mechanisms related to both impaired fasting
glucose (IFG) and IGT [18]. In our study, DM individuals
identified by HbA1c were more insulin resistant than both
N and PD individuals as expected, nonetheless they had
higher beta-cell secretion compared to the N group. This
finding could be possibly explained by a compensatory in-
sulin secretion mechanism in the initial phases of type 2
DM, since individuals were all recently diagnosed.
Regarding cardiovascular risk factors, Di Pino et al.
found that PD according to HbA1c levels selected indi-
viduals with higher cardiovascular risk compared to
those with PD detected by either FPG or OGTT [19].
Our findings of no difference in CV risk among patients
grouped according to FPG are compatible with this previ-
ous study. Among PD individuals identified by HbA1c,
there was a higher proportion of PD individuals having
Framingham risk above 20%, as well as more dyslipidemiaTable 3 Clinical and laboratory features of individuals classifi
Normal (HbA1c < 5.7%)
n (%) 168
Age (years) 57.4 (55.6-59.2)
Weight (kg) 73.4 (71.1-75.7)
BMI (kg/m2) 26.1 (25.0-27.1)
Abdominal circumference (cm) 96.8 (94.9-98.6)
SBP (mmHg) 135.4 (131.8-139.0)
DBP (mmHg) 81.2 (79.0-83.5)
FPG (mg/dL) 97.0 (95.1-98.8)
HOMA2B 68.6 (63.1-74.0)
HOMA2-IR 0.82 (0.70-0.94)
HbA1c (%) 5.31 (5.27-5.35)
HbA1c (mmol/mol) 34.4 (34.0-34.8)
LDL (mg/dL) 100.6 (95.5-105.8)
HDL (mg/dL) 40.9 (38.8-42.9)
Triglycerides (mg/dL) 138.8 (125.8-151.8)
Values expressed in means (95% CI). *p < 0.05 vs. Normal; **p < 0.05 vs. Normal ANDand arterial hypertension when compared to normogly-
cemic subjects. These differences were not observed in the
comparison of PD and normoglycemic individuals diag-
nosed using FPG. Of note, lipid levels, SBP, DBP, and
prevalence of coronary lesion were not different between
groups, neither with FPG nor with HbA1c (Tables 1, 2, 3
and 4). As our study group is composed of outpatients
with high cardiovascular risk referred to coronary angiog-
raphy, this could possibly explain the small difference be-
tween subgroups. Furthermore, the validity of the
Framingham score for predicting future coronary events
in this kind of population could be questioned, since it has
not been designed with this goal.
There is an ongoing controversy about whether FPG
or post load glucose would have a stronger association
with atherosclerosis, and also about which kind of inter-
vention regarding these parameters would modify car-
diovascular risk more effectively [17,20]. The question
about the use of HbA1c for stratification of cardiovascular
risk in PD subjects is under investigation. Di Pino et al.
found that PD diagnosed according to HbA1c levels se-
lected individuals which demonstrated more markers of
atherosclerosis such as increased intima-media thickness
(IMT) than normoglycemic subjects [19]. Similar results
were found in non-diabetic Chinese subjects, in whom
HbA1c demonstrated a more robust association with aor-
tic arterial stiffness than fasting or 2-h post load glucose
levels [21]. On the other hand, compared with subjects
with PD identified by HbA1c only, IGT-only individuals
exhibited significantly more classical and non-classical car-
diovascular risk markers, such as higher SBP and C-ed according to HbA1c levels
Classification according to HbA1c
Prediabetes (HbA1c 5.7-6.4%) Diabetes (HbA1c ≥ 6.5%)
279 67
59.8 (58.6-61.0) 61.5 (59.3-63.7)
71.7 (70.1-73.4) 74.6 (70.3-78.8)
26.0 (25.4-26.7) 27.6 (26.1-29.0)
96.0 (94.4-97.6) 99.9 (96.5-103.3)
138.0 (135.2-140.7) 137.0 (130.7-143.3)
79.8 (77.9-81.6) 79.4 (75.3-83.5)
100.6 (99.2-102.0)* 115.9 (110.3-121.4)**
72.1 (67.6-76.7) 75.5 (62.7-88.2)
0.99 (0.88-1.09) 1.43 (1.13-1.74)**
5.99 (5.97-6.02)* 6.85 (6.72-6.98)**
41.8 (41.6-42.2)* 51.3 (49.9-52.7)**
106.5 (102.0-111.0) 101.0 (90.4-111.5)
41.5 (40.1-42.9) 40.3 (36.8-43.8)
136.9 (128.1-145.8) 148.8 (127.1-170.4)
Prediabetes.
Table 4 Coronary lesions and cardiovascular risk factors of individuals classified according to HbA1c levels
Classification according
to HbA1c
Normal Prediabetes Diabetes p
n 168 279 67
Total coronary lesions 1 [0–3.75] 2 [0–4] 2 [0–5] 0.03*
Framingham risk ≥ 20% (%) 11.8 25.4 26.2 0.006**
CAD (stenosis >
50%) (%)
55.4 61.2 63.6 NS
Hypertension (%) 72.6 87.8 89.6 < 0.001**
Dyslipidemia (%) 72.0 83.8 90.9 < 0.001**
*p for trend, Jonckheere-Terpstra test; **p for linear-by-linear association, Mantel-Haenszel test.
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and insulin sensitivity, resulting in a higher Framingham
score for 10-year CVD risk and subclinical atherosclerosis
as assessed by carotid IMT. However, authors observed no
differences in cardiometabolic risk profile among PD sub-
groups diagnosed by FPG only, HbA1c only, and by both
HbA1c and FPG [18]. In a German study with 8,365 indi-
viduals, HbA1c diagnosed individuals with PD with more
cardiovascular risk factors, but not a higher frequency of
CVD [22]. Another study of 2,076 individuals without DM
showed HbA1c to be independently associated with pro-
gression of coronary artery calcification in 5 years [23].
Moreover, the use of HbA1c for the diagnosis of dys-
glycemia is more recent. Most studies that have ad-
dressed the issue of PD and CVD have used fasting
glucose and/or OGTT as definitions of diagnosis. For ex-
ample, the Australian Diabetes, Obesity, and Lifestyle
Study (AusDiab) showed that the risk of death was in-
creased in those with IFG and IGT, but the risk of CVD
mortality was only significantly higher for those with IFG,
but not IGT, compared with normal glucose tolerance, even
after adjustment for age, sex, and other traditional CVD
risk factors [20]. The WOSCOPS study showed that IFG is
not a good risk marker for CVD, in 6447 middle-aged white
male population over 15 years of follow-up [24]. Further-
more, one systematic review investigated the relative risk
(RR) for CVD associated with IFG and IGT and found only
a modest increase in the risk for CVD with both PD states
[6]. In the Diabetes Prevention Program (DPP), those sub-
jects with IFG and/or IGT that achieved normal glucose
regulation or received specific medical treatment for CVD
risk factors significantly reduced the estimated risk assessed
by the Framingham Risk Score [25].
The use of HbA1c measurements have some advan-
tages over assessments of both FPG or OGTT. Some of
them are very practical concerning patients submitted to
coronary angiography, since no fasting is necessary and
there is less interference during periods of stress [26].
Among the possible explanations for our finding of indi-
viduals with PD identified by HbA1c having highercardiovascular risk than those identified by FPG, we
could speculate that lower levels of HbA1c are more
closely related to postprandial glucose than to FPG
levels. In this regard there are some suggestions that
postprandial glucose in the non-diabetic range is a better
marker of CVD risk [27]. However, this was not con-
firmed by the Emerging Risk Factors Collaboration
study, where the improvement in the prediction of CVD
given by assessment of FPG, postprandial glucose, and
even HbA1c levels were similar. This large prospective
study involving more than 294,000 subjects without
CVD at baseline argues against good incremental benefit
for prediction of CVD with the use of HbA1c [28]. The
same conclusion was found by Schöttker and co-
authors, who showed that in Germans cardiovascular
risk prediction did not improve by adding either FPG or
HbA1c in individuals without diabetes (except for a po-
tential slight improvement in men with HbA1c) [22].
Our study has several limitations. Firstly, we studied in-
dividuals with high cardiovascular risk profile, as they had
clinical indication for cardiac catheterization. Therefore,
our data are not applicable to the general population. In
the same way, there are differences in the hemoglobin
glycation among ethnic groups, which could lead to
discrepancies in the correlation between HbA1c and
FPG levels [29]. Thus the diverse ethnic background
of the Brazilian population could influence this con-
founder [10]. Secondly, another important limitation is
the fact that OGTTs were not performed. We are aware
that the 2-h glucose postload value which allows diag-
nosis of glucose intolerance (PD) is a good marker of
CVD, and may be a good test to identify higher risk
cardiovascular profile [20]. Thirdly, the 50% stenosis
criterion utilized to regard CAD as significant could be
a potential source of bias, since thrombotic events can
occur in patients bearing thinner but unstable plaques.
Finally, an important limitation of our study is the
cross-sectional design, precluding any causal interpre-
tations of associations between PD and the risk of
CAD.
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HbA1c identified individuals with PD bearing a worse car-
diometabolic risk profile as assessed by the Framingham
score and more severe CAD when compared to either
normoglycemic subjects or subjects with PD identified by
FPG, in a sample of high cardiovascular risk individuals.
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